top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


Q3 Pharma Earnings: Portfolio Renewal, Therapeutic-Area Concentration, and the Shift to Innovation-Led Growth
Q3 pharmaceutical results highlight a sector moving beyond pandemic-driven revenues toward innovation-led growth. Demand for obesity and specialty medicines is driving strong performance for companies with differentiated products, while mature and COVID-related portfolios continue to face pressure. Acquisitions and portfolio renewal are reshaping growth prospects, even as one-off costs can obscure underlying performance.
For life sciences leaders, this shift has implications
sharonshieldsconsu
Nov 95 min read


Remember, Remember the Fifth of November: Biotech’s Fireworks, Sparks and Slow Burns
Remember, remember the fifth of November—the night when bonfires burn, fireworks light the sky and everyone looks up to see what will explode next. Biotech has its own Fireworks Night. This year’s display featured headline-grabbing rockets: GLP‑1 deals, gene editing milestones, renewed enthusiasm for RNA and a more disciplined wave of AI‑in‑drug‑discovery stories. But, as every investor knows, not everything that launches reaches the same height.
For biotech insiders and inv
sharonshieldsconsu
Nov 53 min read


Patient Advocacy: A Strategic Partner in Rare Disease Commercialisation
Rare Disease as a Strategic Growth Engine Rare disease is no longer just a scientific or regulatory story — it is a commercial one. But in rare disease, “the market” is not an abstract concept. It is a small, tightly connected ecosystem of patients, caregivers, advocates, clinicians, and payers who all know each other — and who expect to be true partners. Speaking to many global commercial leader over the last few weeks Patient advocacy has been a re-occurring theme. For glob
sharonshieldsconsu
Aug 225 min read


Tilting the Scales: GLP‑1 Drugs, Obesity, and Who Gets to Rewrite Their Biology
GLP‑1 weight‑loss drugs started as diabetes medicines. Now they’re quietly becoming one of the most powerful tools in obesity treatment — and they’re still evolving.
The science is advancing quickly. The harder question is whether access, cost, and policy will keep up.
sharonshieldsconsu
Aug 23 min read
bottom of page